Christopher D. Bayne
Associate
Tel (703) 412-6457

Christopher D. Bayne

Associate

Christopher D. Bayne is a patent attorney in the firm’s Chemical Patent Prosecution group, focusing on patent preparation and prosecution for domestic and international clients in technology areas including, for example, pharmaceuticals, petrochemistry, biotechnology, plastics, polymers, cosmetics, pigments, glass products, light-emitting materials, metallurgy, semiconductors, imaging devices, nanomaterials, and medical devices.

Prior to joining the firm in 2011, Mr. Bayne practiced law as a general litigator in the State of Hawai`i.  Mr. Bayne’s practice focused on complex civil litigation before federal, state and agency courts, with an emphasis on disputes involving contracts, government procurement, torts, health care, construction, land use and foreclosure.

Before attending law school, Mr. Bayne worked as a synthetic-organic (medicinal) chemist in the pharmaceutical/biotech industry.  Mr. Bayne’s industrial research involved the total synthesis and lead optimization of small-molecule therapeutics, including: (i)  Muscarinic (M4) Agonists, as central nervous system therapeutics in the treatment of pain (antinocicepetion); (ii) Liver X Receptor (LXR) Agonists, as cardiovascular therapeutics in the treatment of atherosclerosis; and (ii) Lethal Factor (LF) inhibitors, as bio-defense agents designed to block immune cell-mediated fatality resulting from exposure to Anthrax.  Mr. Bayne is a co-inventor of six issued United States patents relating to his industrial work.

Prior to working as an industrial chemist, Mr. Bayne completed his master’s studies at the Massachusetts Institute of Technology.  There his research focused in the area of supramolecular chemistry, including the design and synthesis of self-complementary molecules capable of self-assembling into three-dimensional dimers.  Mr. Bayne is also the co-author of several academic publications involving synthetic-organic methodology.

Mr. Bayne served in the United States Navy as a propulsion plant operator aboard an Ohio-class submarine.

While attending law school, Mr. Bayne was a published member of the University of Hawai`i Law Review and he interned for two summers at the law firm of McCorriston Miller Mukai MacKinnon LLP in Honolulu, Hawai`i.

Member of the University of Hawai`i Law Review (2008-09)

CALI Excellence for the Future Awards for receiving top grades in Civil Procedure, Food & Drug Law and Second-Year Seminar (WSRSL, 2007-08)

Appellate Advocacy Award for “Best Overall Brief” (WSRSL, 2007)

Outstanding Undergraduate Chemist Award, Orange County, California Section of the American Chemical Society (1994)

Honorman, U.S. Navy Nuclear Power School (Orlando, Florida - 1988)

Academic Publications

Bayne, C.D., Comment, From Anti-Injunction to Radical Reform: Proposing a Unifying Approach to Class-Action Adjudication, 31 U. Haw. L. Rev. 155 (2008)

Miller, S.J.; Bayne, C.D. Diastereoselective Enolsilance Coupling Reactions, J. Org. Chem. 1997, 62, 5680-81

Bayne, C.D. New Directions in Dimeric Self-Assembly, S.M. Thesis, Massachusetts Institute of Technology, Cambridge, MA, 1996

Hiegel, G.A.; Bayne, C.D.; Ridley, B. Conversion of Alkynes into α, α-Dichloroketones and α, α-Dichloromethyl Ketals Using Trichloroisocyanuric Acid, Synth. Comm. 2003, 33(12), 1997-2002

Hiegel, G.A.; Bayne, C.D.; Donde, Y.; Tamashiro, G.S.; Hilberath, L.A. The Oxidation of Aldehydes to Methyl Esters Using Trichloroisocyanuric Acid, Synth. Comm. 1996, 26(14), 2633-39

Hardinger, S.A.; Bayne, C.; Kantorowski, E.; McClellan, Larres, L; Nuesse, M-A. Bis(sulfonyl) Ketones: A New Oxylallyl Cation Source, J. Org. Chem. 1995, 60, 1104-06

 

Issued Patents

  • U.S. Patent No. 7,482,366
  • U.S. Patent No. 7,494,999
  • U.S. Patent No. 7,834,004
  • U.S. Patent No. 7,998,986
  • U.S. Patent No. 7,915,253
  • U.S. Patent No. 8,013,001
Board Applies Mayo Collaborative Servs. v. Prometheus Labs., Inc. and Rejects a Method of Predicting a Response to Treatment as Unpatentable Subject Matter under 35 U.S.C. § 101
Monday, July 23, 2012

In Ex parte Potts (Case No. 2011-004700, in Application Serial No. 11/690,745, decision issued July 17, 2012), the Board rejected as unpatentable subject matter a claimed method for predicting the outcome of a clinical treatment based on measured correlations between treatments and responses, because the claims at issue sought only to...

Product-by-Process Not Obvious Over a Reference ‘Capable of’ Undergoing the Process
Wednesday, May 16, 2012

In Ex parte Babcock (Case No. 2011-011726, in Application Serial No. 10/636,834, decision issued May 9, 2012), the Board reversed the Office’s rejections under 35 U.S.C.

Board Affirms-In-Part and Reverses-In-Part Based On Claim Construction and Design Choice
Thursday, March 08, 2012

In Ex parte Goettsch (Case No. 2011-006303, in Application Serial No. 12/134,270, decision issued March 3, 2012), the Board affirmed-in-part and reversed-in-part the Examiner’s rejections under 35 U.S.C.

All Blogs